Literature DB >> 2076740

Laboratory screening method for selection of healthy volunteers.

M Sibille1, D Vital Durand.   

Abstract

The aim of laboratory screening in Phase I is to exclude subjects with subclinical illness, who might be at increased risk in the study, and who might also adversely influence interpretation of the results. A new method for laboratory screening, based on Bayesian probability theory, is proposed, which consists of: 1. Drawing up a list of diseases to be excluded. 2. Defining for each disease, the maximum acceptable risk that an included subject could be affected by it. 3. Identifying one test for each disease. 4. Using a contingency table to calculate the specificity of the test and integrating the estimated prevalence of the disease from epidemiological data. 5. Applying the percentage obtained by the calculation of specificity to the previously determined distribution of values in the volunteer population to identify the threshold value for inclusion. Use of this deductive method in screening volunteers for Phase I trials affords increased security of selection, while reducing the number of non-pertinent exclusions because of laboratory findings.

Mesh:

Year:  1990        PMID: 2076740     DOI: 10.1007/BF00280939

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Commentary. The normal volunteer in clinical investigation: how rigid should selection criteria be?

Authors:  P Joubert; L Rivera-Calimlim; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

2.  Evaluation of the prison inmate as a subject in drug assessment.

Authors:  J J Schrogie; M J Hensley; C Digiore; S Harris
Journal:  Clin Pharmacol Ther       Date:  1977-01       Impact factor: 6.875

3.  Informed consent of volunteers: a direct measurement of comprehension and retention of information.

Authors:  W E Woodward
Journal:  Clin Res       Date:  1979-09

4.  Judgment based on 95 per cent confidence limits: a statistical dilemma involving multitest screening and proficiency testing of multiple specimens.

Authors:  I Schoen; S H Brooks
Journal:  Am J Clin Pathol       Date:  1970-02       Impact factor: 2.493

5.  The selection of healthy volunteers for clinical investigation: the case for volunteer pools.

Authors:  P Joubert; P Pannall
Journal:  Curr Med Res Opin       Date:  1976       Impact factor: 2.580

  5 in total
  4 in total

1.  Adverse events in phase one studies: a study in 430 healthy volunteers.

Authors:  M Sibille; N Deigat; V Olagnier; D V Durand; R Levrat
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Factors influencing recruitment and retention of participants in clinical studies conducted at a tertiary referral center: A five-year audit.

Authors:  Debdipta Bose; Shruti Saha; Unnati Saxena; Harshad Kesari; Urmila M Thatte; Nithya J Gogtay
Journal:  Perspect Clin Res       Date:  2020-05-06

3.  Upper limit of plasma alanine amino transferase during phase I studies.

Authors:  M Sibille; L G Lassonery; A Janin; N Deigat; B Boutouyrie; D V Durand
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes.

Authors:  Annemie Deiteren; Erwin Coenen; Sabine Lenders; Peter Verwilst; Erik Mannaert; Freya Rasschaert
Journal:  Clin Transl Sci       Date:  2021-08-11       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.